{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:18:39Z","timestamp":1791566319809,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Polypharmacy is a common problem in older adults with hip fractures and may negatively affect postoperative outcomes. The aim of this study was to evaluate the association between polypharmacy, including severe polypharmacy, and clinical outcomes in older adults admitted to hospital with hip fracture. A real-life observational study was conducted at a tertiary care hospital in Spain, including patients aged\u2009\u2265\u200970\u00a0years who underwent hip fracture surgery between January 1, 2017, and December 31, 2018. Data were extracted from electronic medical records, including demographic details, comorbidities, and medication use. Polypharmacy was defined as the use of five or more medications, and severe polypharmacy as the use of ten or more medications. Mortality rates were analyzed at 30\u00a0days, 6\u00a0months, 1\u00a0year, 2\u00a0years, and 5\u00a0years post-surgery using Kaplan\u2013Meier survival curves and Cox regression analysis. Among 644 patients included (mean age 84.5\u00a0years, 70.5% women), 63.8% had polypharmacy and 19.1% had severe polypharmacy. Compared with patients without polypharmacy, those with polypharmacy, regardless of severity, showed higher mortality at 30\u00a0days (8.4% and 10.3% vs 3.9%), 6\u00a0months (21.3% and 21.4% vs 10.8%), 1\u00a0year (26.6% and 33.3% vs 11.6%), 2\u00a0years (38.8% and 46.0% vs 14.2%), and 5\u00a0years (68.5% and 76.2% vs 26.3%) (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20090.05). Crude hazard ratios for 5-year mortality were 3.65 (95% CI 2.73\u20134.88) for patients taking 5\u20139 drugs and 4.51 (95% CI 3.26\u20136.24) for those taking\u2009\u2265\u200910 drugs; after full adjustment, these remained 3.12 and 3.46, respectively. Patients with polypharmacy also had more red blood cell transfusions, major complications, and worse functional recovery. Polypharmacy was associated with worse postoperative morbidity, poorer functional recovery, and higher mortality in older adults with hip fracture. These findings suggest that medication burden may serve as a marker of clinical vulnerability rather than an isolated causal factor. Prospective interventional studies are needed to determine whether medication optimization improves outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-52300-5","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:50:42Z","timestamp":1778248242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence of the impact of polypharmacy on mortality and recovery after hip fracture in elderly patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Elisa","family":"Garc\u00eda-Tercero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Valcuende-Rosique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Valcuende-Rosique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Andrea Villalon","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Navalon","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cunha-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Vi\u00f1a","family":"Ribes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Tarazona-Santabalbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"52300_CR1","unstructured":"World Health Organization (WHO). At https:\/\/www.unfpa.org\/es\/data\/world-population-dashboard. (Consulted on May 30, 2024)."},{"key":"52300_CR2","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Proyecciones de Poblaci\u00f3n 2021\u20132070. En: https:\/\/www.ine.es\/prodyser\/pubweb\/proydemog2021.htm. (Consulted on May 30, 2024)."},{"key":"52300_CR3","unstructured":"Servicio Madrile\u00f1o de Salud (SMS). Observatorio de resultados del SMS. En http:\/\/observatorioresultados.sanidadmadrid.org. (Consulted on May 30, 2024)."},{"key":"52300_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/CIA.S291071","volume":"16","author":"YW Zhang","year":"2021","unstructured":"Zhang, Y. W. et al. Prevalence, characteristics and associated risk factor of the elderly with hip fractures: A cross-sectional analysis of NHANES 2005\u20132010. Clin. Interv. Aging 16, 177\u2013185. https:\/\/doi.org\/10.2147\/CIA.S291071 (2021).","journal-title":"Clin. Interv. Aging"},{"key":"52300_CR5","doi-asserted-by":"publisher","first-page":"1006527","DOI":"10.3389\/fpubh.2023.1006527","volume":"11","author":"Y Yu","year":"2023","unstructured":"Yu, Y., Wang, Y., Hou, X. & Tian, F. Recent advances in the identification of related factors and preventive strategies of hip fracture. Front. Public Health 11, 1006527. https:\/\/doi.org\/10.3389\/fpubh.2023.1006527 (2023).","journal-title":"Front. Public Health"},{"issue":"4","key":"52300_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/21551197.2011.623931","volume":"30","author":"RA Heuberger","year":"2011","unstructured":"Heuberger, R. A. The frailty syndrome: A comprehensive review. J Nutr Gerontol Geriatr 30(4), 315\u2013368. https:\/\/doi.org\/10.1080\/21551197.2011.623931 (2011).","journal-title":"J Nutr Gerontol Geriatr"},{"key":"52300_CR7","doi-asserted-by":"publisher","first-page":"890652","DOI":"10.3389\/fpubh.2022.890652","volume":"10","author":"Y Song","year":"2022","unstructured":"Song, Y., Wu, Z., Huo, H. & Zhao, P. The impact of frailty on adverse outcomes in geriatric hip fracture patients: A systematic review and meta-analysis. Front. Public Health 10, 890652. https:\/\/doi.org\/10.3389\/fpubh.2022.890652 (2022).","journal-title":"Front. Public Health"},{"issue":"12","key":"52300_CR8","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1007\/s00264-022-05605-9","volume":"46","author":"B Yan","year":"2022","unstructured":"Yan, B. et al. Prognostic significance of frailty in older patients with hip fracture: A systematic review and meta-analysis. Int. Orthop. 46(12), 2939\u20132952. https:\/\/doi.org\/10.1007\/s00264-022-05605-9 (2022).","journal-title":"Int. Orthop."},{"key":"52300_CR9","unstructured":"P\u00e9rez N, Mateos del Nozal J. Valoraci\u00f3n geri\u00e1trica como instrumento. En Manual del residente en geriatr\u00eda. 2011. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. ISBN: 978-84-695-0862-6."},{"issue":"12","key":"52300_CR10","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.3390\/nu12123743","volume":"12","author":"T Inoue","year":"2020","unstructured":"Inoue, T. et al. Undernutrition, sarcopenia, and frailty in fragility hip fracture: Advanced strategies for improving clinical outcomes. Nutrients 12(12), 3743. https:\/\/doi.org\/10.3390\/nu12123743 (2020).","journal-title":"Nutrients"},{"key":"52300_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2019.04.212","volume":"126","author":"R O\u2019Caoimh","year":"2019","unstructured":"O\u2019Caoimh, R. et al. Reducing inappropriate prescribing for older adults with advanced frailty: A review based on a survey of practice in four countries. Maturitas 126, 1\u201310. https:\/\/doi.org\/10.1016\/j.maturitas.2019.04.212 (2019).","journal-title":"Maturitas"},{"issue":"1","key":"52300_CR12","doi-asserted-by":"publisher","first-page":"16831","DOI":"10.1038\/s41598-023-43876-3","volume":"13","author":"T Uematsu","year":"2023","unstructured":"Uematsu, T. et al. Association between number of medications and hip fractures in Japanese elderly using conditional logistic LASSO regression. Sci. Rep. 13(1), 16831 (2023).","journal-title":"Sci. Rep."},{"key":"52300_CR13","doi-asserted-by":"publisher","first-page":"215145932412344","DOI":"10.1177\/21514593241234431","volume":"15","author":"T Taniguchi","year":"2024","unstructured":"Taniguchi, T. et al. Polypharmacy of older surgical patients with extremity fractures. Geriatr. Orthop. Surg. Rehabil. 15, 21514593241234430 (2024).","journal-title":"Geriatr. Orthop. Surg. Rehabil."},{"issue":"4","key":"52300_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.medcli.2018.12.013","volume":"153","author":"M Guti\u00e9rrez-Valencia","year":"2019","unstructured":"Guti\u00e9rrez-Valencia, M. et al. Prevalencia de polifarmacia y factores asociados en adultos mayores en Espa\u00f1a: datos de la Encuesta Nacional de Salud 2017. Med. Clin. North Am. 153(4), 141\u2013150. https:\/\/doi.org\/10.1016\/j.medcli.2018.12.013 (2019).","journal-title":"Med. Clin. North Am."},{"key":"52300_CR15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0406","author":"MR Mohamed","year":"2020","unstructured":"Mohamed, M. R. et al. Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: A systematic review and meta-analysis. Oncologist https:\/\/doi.org\/10.1634\/theoncologist.2019-0406 (2020).","journal-title":"Oncologist"},{"key":"52300_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2147\/CIA.S101832","volume":"11","author":"A Kragh Ekstam","year":"2016","unstructured":"Kragh Ekstam, A. & Elmst\u00e5hl, S. Do fall-risk-increasing drugs have an impact on mortality in older hip fracture patients? A population-based cohort study. Clin. Interv. Aging 11, 489\u2013496. https:\/\/doi.org\/10.2147\/CIA.S101832 (2016).","journal-title":"Clin. Interv. Aging"},{"issue":"1","key":"52300_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13018-016-0486-7","volume":"11","author":"M H\u00e4rstedt","year":"2016","unstructured":"H\u00e4rstedt, M., Rogmark, C., Sutton, R., Melander, O. & Fedorowski, A. Polypharmacy and adverse outcomes after hip fracture surgery. J. Orthop. Surg. Res. 11(1), 151. https:\/\/doi.org\/10.1186\/s13018-016-0486-7 (2016).","journal-title":"J. Orthop. Surg. Res."},{"issue":"6","key":"52300_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.6061\/clinics\/2012(06)02","volume":"67","author":"FJ Tarazona-Santabalbina","year":"2012","unstructured":"Tarazona-Santabalbina, F. J. et al. Early interdisciplinary hospital intervention for elderly patients with hip fractures: Functional outcome and mortality. Clinics 67(6), 547\u2013556. https:\/\/doi.org\/10.6061\/clinics\/2012(06)02 (2012).","journal-title":"Clinics"},{"issue":"3","key":"52300_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","volume":"12","author":"F Pazan","year":"2021","unstructured":"Pazan, F. & Wehling, M. Polypharmacy in older adults: A narrative review of definitions, epidemiology and consequences. Eur. Geriatr. Med. 12(3), 443\u2013452. https:\/\/doi.org\/10.1007\/s41999-021-00479-3 (2021).","journal-title":"Eur. Geriatr. Med."},{"issue":"1","key":"52300_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12877-022-03388-7","volume":"22","author":"M Delara","year":"2022","unstructured":"Delara, M. et al. Prevalence and factors associated with polypharmacy: A systematic review and Meta-analysis. BMC Geriatr. 22(1), 601. https:\/\/doi.org\/10.1186\/s12877-022-03388-7 (2022).","journal-title":"BMC Geriatr."},{"issue":"5","key":"52300_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40(5), 373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8 (1987).","journal-title":"J. Chronic Dis."},{"issue":"1","key":"52300_CR22","first-page":"38","volume":"20","author":"IJ de Ul\u00edbarri","year":"2005","unstructured":"de Ul\u00edbarri, I. J. et al. CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 20(1), 38\u201345 (2005).","journal-title":"Nutr Hosp"},{"issue":"10","key":"52300_CR23","doi-asserted-by":"publisher","first-page":"e47089","DOI":"10.7759\/cureus.47089","volume":"15","author":"Y Al-Khatib","year":"2023","unstructured":"Al-Khatib, Y. & Dasari, K. Hip fracture post-operative mortality and polypharmacy: A new risk predictor?. Cureus 15(10), e47089. https:\/\/doi.org\/10.7759\/cureus.47089 (2023).","journal-title":"Cureus"},{"issue":"1","key":"52300_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40261-018-0716-3","volume":"39","author":"HY Park","year":"2019","unstructured":"Park, H. Y., Kim, S., Sohn, H. S. & Kwon, J. W. The association between polypharmacy and hip fracture in osteoporotic women: A nested case-control study in South Korea. Clin. Drug Investig. 39(1), 63\u201371. https:\/\/doi.org\/10.1007\/s40261-018-0716-3 (2019).","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"52300_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.amjopharm.2012.02.003","volume":"10","author":"F Mizokami","year":"2012","unstructured":"Mizokami, F., Koide, Y., Noro, T. & Furuta, K. Polypharmacy with common diseases in hospitalized elderly patients. Am. J. Geriatr. Pharmacother. 10(2), 123\u2013128. https:\/\/doi.org\/10.1016\/j.amjopharm.2012.02.003 (2012).","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"52300_CR26","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.141219","author":"WH Lu","year":"2015","unstructured":"Lu, W. H., Wen, Y. W., Chen, L. K. & Hsiao, F. Y. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: A retrospective cohort study. CMAJ https:\/\/doi.org\/10.1503\/cmaj.141219 (2015).","journal-title":"CMAJ"},{"issue":"11","key":"52300_CR27","doi-asserted-by":"publisher","first-page":"1067.e1","DOI":"10.1016\/j.jamda.2016.08.019","volume":"17","author":"S Lalic","year":"2016","unstructured":"Lalic, S. et al. Polypharmacy and medication regimen complexity as risk factors for hospitalization among residents of long-term care facilities: A prospective cohort study. J. Am. Med. Dir. Assoc. 17(11), 1067.e1-1067.e6. https:\/\/doi.org\/10.1016\/j.jamda.2016.08.019 (2016).","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"1","key":"52300_CR28","doi-asserted-by":"publisher","first-page":"18964","DOI":"10.1038\/s41598-020-75888-8","volume":"10","author":"TI Chang","year":"2020","unstructured":"Chang, T. I. et al. Polypharmacy, hospitalization, and mortality risk: A nationwide cohort study. Sci. Rep. 10(1), 18964. https:\/\/doi.org\/10.1038\/s41598-020-75888-8 (2020).","journal-title":"Sci. Rep."},{"issue":"9","key":"52300_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40266-017-0482-6","volume":"34","author":"A Iaboni","year":"2017","unstructured":"Iaboni, A., Rawson, K., Burkett, C., Lenze, E. J. & Flint, A. J. Potentially inappropriate medications and the time to full functional recovery after hip fracture. Drugs Aging 34(9), 723\u2013728. https:\/\/doi.org\/10.1007\/s40266-017-0482-6 (2017).","journal-title":"Drugs Aging"},{"issue":"4","key":"52300_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/bja\/aes187","volume":"109","author":"IK Moppett","year":"2012","unstructured":"Moppett, I. K. et al. Nottingham hip fracture score: Longitudinal and multi-assessment. Br J Anaesth. 109(4), 546\u2013550. https:\/\/doi.org\/10.1093\/bja\/aes187 (2012).","journal-title":"Br J Anaesth."},{"key":"52300_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3238\/arztebl.m2022.0377","volume":"120","author":"NK Mann","year":"2023","unstructured":"Mann, N. K. et al. Potentially inadequate medications in the elderly: PRISCUS 2.0. Dtsch Arztebl Int 120, 3\u201310. https:\/\/doi.org\/10.3238\/arztebl.m2022.0377 (2023).","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"52300_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/13607863.2018.1468411","volume":"23","author":"N Leelakanok","year":"2019","unstructured":"Leelakanok, N. & D\u2019Cunha, R. R. Association between polypharmacy and dementia\u2014A systematic review and metaanalysis. Aging Ment Health 23(8), 932\u2013941. https:\/\/doi.org\/10.1080\/13607863.2018.1468411 (2019).","journal-title":"Aging Ment Health"},{"issue":"1","key":"52300_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13018-023-03906-2","volume":"18","author":"BT Henriksen","year":"2023","unstructured":"Henriksen, B. T. et al. Clinical pharmacist intervention to improve medication safety for hip fracture patients through secondary and primary care settings: a nonrandomised controlled trial. J. Orthop. Surg. Res. 18(1), 434. https:\/\/doi.org\/10.1186\/s13018-023-03906-2 (2023).","journal-title":"J. Orthop. Surg. Res."},{"issue":"8","key":"52300_CR34","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/jgs.19572","volume":"73","author":"E Bj\u00f8rk","year":"2025","unstructured":"Bj\u00f8rk, E. et al. Polypharmacy\u2019s association with mortality: confounding from underlying morbidity. J. Am. Geriatr. Soc. 73(8), 2485\u20132493. https:\/\/doi.org\/10.1111\/jgs.19572 (2025).","journal-title":"J. Am. Geriatr. Soc."},{"key":"52300_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2022.102367","author":"RA Garc\u00eda","year":"2022","unstructured":"Garc\u00eda, R. A., Baena, J. M., Herreros, Y. & Acosta, M. A. Deprescripci\u00f3n en personas mayores: es el momento de pasar a la acci\u00f3n. Aten. Primaria https:\/\/doi.org\/10.1016\/j.aprim.2022.102367 (2022).","journal-title":"Aten. Primaria"},{"key":"52300_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jgs.18372","volume":"2023","author":"Update Expert Panel. American Geriatrics Society","year":"2023","unstructured":"Update Expert Panel. American Geriatrics Society. Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr Soc. 2023, 1\u201330. https:\/\/doi.org\/10.1111\/jgs.18372 (2023).","journal-title":"J. Am. Geriatr Soc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52300-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:23:51Z","timestamp":1783470231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52300-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52300"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52300-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by institutional Ethics and Clinical Research Committee (registration code HULR23122022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21135"}}